MTRX 1011A / Tolerx, Roche - LARVOL DELTA

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments (Arthritis Res Ther) - P1, N=NA; MTRX1011A was well tolerated in the single ascending dose (SAD) phase up to 7 mg/kg IV and in the multi dose (MD) phase up to 1.5 mg/kg SC; Reduction in disease activity was modest; PD assessments demonstrated that MTRX1011A induced a dose-dependent down modulation of CD4 expression on peripheral blood CD4 T cells, CD4 receptor occupancy, increases in serum sCD4-MTRX1011A complexes & up-regulation of CD69 on T cells, but was non-depleting

P1 data • Rheumatoid Arthritis

Novogen and CanTx announce potency of intra-peritoneal Trx-1 confirmed against chemo-resistant ovarian cancer stem cells (Market Watch) - "Novogen Limited and CanTx Inc...today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity...Novogen and CanTx plan to file an Investigational New Drug application (IND) with the FDA in early 2015 and to start a Phase 1 study by mid-2015."

Anticipated IND • Anticipated new P1 trial • Preclinical • Oncology • Ovarian Cancer